Driving Proof-of-Mechanism & Scalable Treg Therapy Development
- Translating discovery into the clinic by driving research from early discovery through preclinical validation, ensuring robust study design, regulatory alignment, and effective transition of lab findings into first-in-human studies
- Leveraging a tetramer-based assay to directly measure antigen-specific Treg populations, enabling precise proof-of-mechanism validation
- Establishing scalable GMP manufacturing processes that bridge scientific innovation and clinical application, ensuring efficient development of patient-ready therapeutics